D007680DisordersC04.588.945.947.535C12.758.820.750C12.777.419.473C13.351.937.820.535C13.351.968.419.4731406200.652846Kidney Neoplasmsprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson14.44430.00487281140research area of0.9926260.00624092526subject area for36971500Meza L, Zengin Z, Salgia S, Malhotra J, Karczewska E, Dorff T, Tripathi A, Ely J, Kelley E, Mead H, Hsu J, Dizman N, Salgia N, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Rock A, Liu S, Salgia R, Trent J, Altin J, Pal SKThe oncologistTwelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. Oncologist. 2023 09 07; 28(9):e748-e755.Oncologist2023-09-07T00:00:002023Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis.37226477Paik J, Ellis CL, Henriksen KJ, Chang AInternational journal of surgical pathologyAn International Survey of Genitourinary and Renal Pathologists Regarding Evaluation of the Non-Neoplastic Parenchyma in Kidney Cancer Specimens. Int J Surg Pathol. 2024 Apr; 32(2):273-278.Int J Surg Pathol2023-05-24T00:00:002023An International Survey of Genitourinary and Renal Pathologists Regarding Evaluation of the Non-Neoplastic Parenchyma in Kidney Cancer Specimens.MedicinePathologySurgeryUniversity of ChicagoScott E.EggenerScott E. Eggener41.78927490000000-87.601250000000001156Eggener, Scott E.ProfessorGladell P.PanerGladell P. Paner41.78927490000000-87.60125000000000146Paner, Gladell P.ProfessorAriehShalhavArieh Shalhav41.78927490000000-87.601250000000001625Shalhav, AriehProfessorTatjanaAnticTatjana Antic41.78927490000000-87.601250000000001672Antic, TatjanaProfessorWalter M.StadlerWalter M. Stadler41.78927490000000-87.601250000000001904Stadler, Walter M.Professor38340966Lerma LA, Pease G, Malleis J, Antic T, Hes O, Tretiakova MHuman pathologyActual encounters of the kidney kind: Exploring 48 cases of renal collision tumors through the lens of literature. Hum Pathol. 2024 Mar; 145:26-33.Hum Pathol2024-02-08T00:00:002024Actual encounters of the kidney kind: Exploring 48 cases of renal collision tumors through the lens of literature.38394781Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LAJournal of the National Comprehensive Cancer Network : JNCCNNCCN GuidelinesĀ® Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024 02; 22(1):4-16.J Natl Compr Canc Netw2024-02-01T00:00:002024NCCN GuidelinesĀ® Insights: Kidney Cancer, Version 2.2024.38372949Beckermann KE, Patnaik A, Winer I, Tan W, Bashir B, Kyriakopoulos CE, Sweis RF, Chamberlain M, Rini BIInvestigational new drugsA phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma. Invest New Drugs. 2024 Apr; 42(2):179-184.Invest New Drugs2024-02-19T00:00:002024A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessorSurgery-Urology